open access

Vol 69, No 5 (2018)
Original Paper
Published online: 2018-08-14
Submitted: 2018-06-10
Accepted: 2018-06-21
Get Citation

Plasma adiponectin array in women with Alzheimer’s disease

Agnieszka Baranowska-Bik, Małgorzata Kalisz, Lidia Martyńska, Ewa Wolińska-Witort, Maria Styczyńska, Małgorzata Chodakowska-Żebrowska, Maria Barcikowska, Bogusława Baranowska, Wojciech Bik
DOI: 10.5603/EP.a2018.0055
·
Pubmed: 30117532
·
Endokrynologia Polska 2018;69(5):550-559.

open access

Vol 69, No 5 (2018)
Original Paper
Published online: 2018-08-14
Submitted: 2018-06-10
Accepted: 2018-06-21

Abstract

ABSTRACT Introduction Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease. Typical features of AD include memory loss, social dysfunction and physical impairment. Although the pathological findings in the central nervous system are well established, the etiological factors are poorly known. Recent studies suggested the role of metabolic disturbances in the development of AD neurodegeneration. Adiponectin, an anti-inflammatory and metabolism regulating factor, was linked to AD. Aim The aim was to examine whether adiponectin fractions combined with insulin/insulin resistance-associated metabolic parameters correlate with AD progression. Material and methods The study comprised 98 women: 27 with moderate to severe AD, 31 with AD at early stage and 40 healthy controls, matched for age and BMI. To evaluate memory impairment, the MMSE was performed. Plasma total adiponectin and its high-, medium- and low molecular weights were measured with ELISA. Anthropometric, clinical and metabolic parameters were assessed. Correlations between adiponectin array and measured parameters were evaluated. Results In comparison to the controls, enhanced levels of total and medium molecular weight adiponectin characterized AD individuals. In AD, we found correlations between adiponectin array, and anthropometric and biochemical parameters. After adjustment to BMI, a significant increase of the total adiponectin and high- and medium molecular weight fractions was observed. A negative correlation between low molecular weight adiponectin and MMSE was found. Conclusions Our results indicate a possible link between adiponectin variations and AD. We hypothesize that changes in adiponectin profile observed in AD result from compensatory mechanism against neuropathological processes, as well as from adiponectin homeostasis impairment.

Abstract

ABSTRACT Introduction Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease. Typical features of AD include memory loss, social dysfunction and physical impairment. Although the pathological findings in the central nervous system are well established, the etiological factors are poorly known. Recent studies suggested the role of metabolic disturbances in the development of AD neurodegeneration. Adiponectin, an anti-inflammatory and metabolism regulating factor, was linked to AD. Aim The aim was to examine whether adiponectin fractions combined with insulin/insulin resistance-associated metabolic parameters correlate with AD progression. Material and methods The study comprised 98 women: 27 with moderate to severe AD, 31 with AD at early stage and 40 healthy controls, matched for age and BMI. To evaluate memory impairment, the MMSE was performed. Plasma total adiponectin and its high-, medium- and low molecular weights were measured with ELISA. Anthropometric, clinical and metabolic parameters were assessed. Correlations between adiponectin array and measured parameters were evaluated. Results In comparison to the controls, enhanced levels of total and medium molecular weight adiponectin characterized AD individuals. In AD, we found correlations between adiponectin array, and anthropometric and biochemical parameters. After adjustment to BMI, a significant increase of the total adiponectin and high- and medium molecular weight fractions was observed. A negative correlation between low molecular weight adiponectin and MMSE was found. Conclusions Our results indicate a possible link between adiponectin variations and AD. We hypothesize that changes in adiponectin profile observed in AD result from compensatory mechanism against neuropathological processes, as well as from adiponectin homeostasis impairment.
Get Citation

Keywords

adiponectin; adiponectin fractions; Alzheimer’s disease

About this article
Title

Plasma adiponectin array in women with Alzheimer’s disease

Journal

Endokrynologia Polska

Issue

Vol 69, No 5 (2018)

Pages

550-559

Published online

2018-08-14

DOI

10.5603/EP.a2018.0055

Pubmed

30117532

Bibliographic record

Endokrynologia Polska 2018;69(5):550-559.

Keywords

adiponectin
adiponectin fractions
Alzheimer’s disease

Authors

Agnieszka Baranowska-Bik
Małgorzata Kalisz
Lidia Martyńska
Ewa Wolińska-Witort
Maria Styczyńska
Małgorzata Chodakowska-Żebrowska
Maria Barcikowska
Bogusława Baranowska
Wojciech Bik

References (51)
  1. Gustafson DR. Adiposity and cognitive decline: underlying mechanisms. J Alzheimers Dis. 2012; 30 Suppl 2: S97–112.
  2. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006; 368(9533): 387–403.
  3. Sims-Robinson C, Kim B, Rosko A, et al. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010; 6(10): 551–559.
  4. Whitmer RA, Gunderson EP, Quesenberry CP, et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res. 2007; 4(2): 103–109.
  5. Grundy SM. Adipose tissue and metabolic syndrome: too much, too little or neither. Eur J Clin Invest. 2015; 45(11): 1209–1217.
  6. Upadhyay J, Farr O, Perakakis N, et al. Obesity as a Disease. Med Clin North Am. 2018; 102(1): 13–33.
  7. Choi CH, Cohen P. Adipose crosstalk with other cell types in health and disease. Exp Cell Res. 2017; 360(1): 6–11.
  8. Sirbu AE, Buburuzan L, Kevorkian S, et al. Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity. Endokrynol Pol. 2018; 69(3): 252–258.
  9. Siemińska L, Borowski A, Marek B, et al. Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol Pol. 2018; 69(2): 120–127.
  10. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012; 55(9): 2319–2326.
  11. Liu M, Liu F. Regulation of adiponectin multimerization, signaling and function. Best Pract Res Clin Endocrinol Metab. 2014; 28(1): 25–31.
  12. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008; 32 Suppl 7: S13–S18.
  13. Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016; 8(2): 93–100.
  14. Waragai M, Ho G, Takamatsu Y, et al. Importance of adiponectin activity in the pathogenesis of Alzheimer's disease. Ann Clin Transl Neurol. 2017; 4(8): 591–600.
  15. Letra L, Rodrigues T, Matafome P, et al. Adiponectin and sporadic Alzheimer's disease: Clinical and molecular links. Front Neuroendocrinol. 2017 [Epub ahead of print].
  16. Ng RCL, Chan KH. Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease. Int J Mol Sci. 2017; 18(3).
  17. Rivero O, Sich S, Popp S, et al. Impact of the ADHD-susceptibility gene CDH13 on development and function of brain networks. Eur Neuropsychopharmacol. 2013; 23(6): 492–507.
  18. Thundyil J, Pavlovski D, Sobey CG, et al. Adiponectin receptor signalling in the brain. Br J Pharmacol. 2012; 165(2): 313–327.
  19. Ng RCL, Cheng OY, Jian M, et al. Chronic adiponectin deficiency leads to Alzheimer's disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice. Mol Neurodegener. 2016; 11(1): 71.
  20. Kim MW, Abid NB, Jo MH, et al. Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer's disease-like pathologies. Sci Rep. 2017; 7(1): 12435.
  21. Várhelyi ZP, Kálmán J, Oláh Z, et al. Adiponectin Receptors Are Less Sensitive to Stress in a Transgenic Mouse Model of Alzheimer's Disease. Front Neurosci. 2017; 11: 199.
  22. de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol. 2014; 88(4): 548–559.
  23. Vieira MNN, Lima-Filho RAS, De Felice FG. Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. Neuropharmacology. 2018; 136(Pt B): 160–171.
  24. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016; 8(2): 101–109.
  25. Bloom GS, Lazo JS, Norambuena A. Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis. Neuropharmacology. 2018; 136(Pt B): 192–195.
  26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7): 939–944.
  27. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3): 263–269.
  28. Godoy JA, Rios JA, Zolezzi JM, et al. Signaling pathway cross talk in Alzheimer's disease. Cell Commun Signal. 2014; 12: 23.
  29. Kang S, Lee YHo, Lee JE. Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Med J. 2017; 58(3): 479–488.
  30. Llorens-Martín M, Jurado J, Hernández F, et al. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7: 46.
  31. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 2008; 582(1): 74–80.
  32. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci. 2012; 32(30): 10117–10128.
  33. Song J, Lee JE. Adiponectin as a new paradigm for approaching Alzheimer's disease. Anat Cell Biol. 2013; 46(4): 229–234.
  34. Arnoldussen IAC, Kiliaan AJ, Gustafson DR. Obesity and dementia: adipokines interact with the brain. Eur Neuropsychopharmacol. 2014; 24(12): 1982–1999.
  35. Yau SYu, Li A, Hoo RLC, et al. Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin. Proc Natl Acad Sci U S A. 2014; 111(44): 15810–15815.
  36. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018; 14(3): 133–150.
  37. Kitagawa K, Miwa K, Okazaki S, et al. Serum high-molecular-weight adiponectin level and incident dementia in patients with vascular risk factors. Eur J Neurol. 2016; 23(3): 641–647.
  38. Kusminski CM, McTernan PG, Schraw T, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia. 2007; 50(3): 634–642.
  39. Waragai M, Adame A, Trinh I, et al. Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease. J Alzheimers Dis. 2016; 52(4): 1453–1459.
  40. Une K, Takei YA, Tomita N, et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol. 2011; 18(7): 1006–1009.
  41. Khemka VK, Bagchi D, Bandyopadhyay K, et al. Altered serum levels of adipokines and insulin in probable Alzheimer's disease. J Alzheimers Dis. 2014; 41(2): 525–533.
  42. Ma J, Zhang W, Wang HF, et al. Peripheral Blood Adipokines and Insulin Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analysis. Curr Alzheimer Res. 2016; 13(3): 223–233.
  43. van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. Arch Neurol. 2012; 69(5): 594–600.
  44. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis. 2012; 29(1): 151–157.
  45. Bigalke B, Schreitmüller B, Sopova K, et al. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One. 2011; 6(5): e20286.
  46. Dukic L, Simundic AM, Martinic-Popovic I, et al. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Clin Biochem. 2016; 49(3): 213–218.
  47. Teixeira AL, Diniz BS, Campos AC, et al. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromolecular Med. 2013; 15(1): 115–121.
  48. Diehl T, Mullins R, Kapogiannis D. Insulin resistance in Alzheimer's disease. Transl Res. 2017; 183: 26–40.
  49. Mittal K, Katare DP. Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review. Diabetes Metab Syndr. 2016; 10(2 Suppl 1): S144–S149.
  50. Leng Y, Karlsson HKR, Zierath JR. Insulin signaling defects in type 2 diabetes. Rev Endocr Metab Disord. 2004; 5(2): 111–117.
  51. Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004; 63(7): 1187–1192.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl